India to Turkey: Salmeterol Export Trade Route

The India to Turkey Salmeterol corridor is one of India's established pharmaceutical export routes, with 78 shipments documented worth a combined $7.9M USD. The route is dominated by CIPLA LIMITED, which alone accounts for roughly 53% of all export value, reflecting the consolidated nature of India's salmeterol manufacturing sector.

Across 7 active suppliers, the average shipment value stands at $101.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 81% of all shipments, consistent with salmeterol's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 24 days port-to-port. The route has recorded an annual growth rate of 21.2%, placing it at rank #18 among India's top salmeterol export destinations globally.

On the import side, key buyers of Indian salmeterol in Turkey include PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR, HAWKARY COMPANY FOR GENERAL TRADING , PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR and 4 others. PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR is the single largest importer with 64 shipments valued at $7.3M USD.

India's salmeterol exports to Turkey are driven primarily by a handful of large-scale manufacturers. CIPLA LIMITED with 43 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 7 active exporters signals a competitive but concentrated market — buyers in Turkey benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — CIPLA LIMITED, MEDISPRAY LABORATORIES PRIVATE LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED — together account for 97% of total trade value on this route. The average shipment value of $101.1K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as seroflo 250 hfa inhaler salmeterol xina and seroflo 125 hfa inhaler (with dose indicator) (salmeterol xinafoate 25mcg+fluticasone propionate 125mcg ) (1 x 120 md), suggesting that buyers in Turkey tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR is the largest importer with 64 shipments worth $7.3M USD — representing 92% of all salmeterol imports from India on this route. A total of 7 buyers are active on this corridor.